News about "vivo CAR-T Therapy"

Pfizer Signs USD 2.6 Billion Deal with Starna Therapeutics for In Vivo CAR-T Therapies

Pfizer Signs USD 2.6 Billion Deal with Starna Therapeutics for In Vivo CAR-T Therapies

Pfizer signs USD 2.6 billion deal with China’s Starna Therapeutics to secure ex-China rights to three preclinical in vivo CAR-T programmes targeting autoimmune diseases, marking its entry into the field.

Vivo CAR-T Therapy | 20/11/2026 | By News Bureau

RiboX Wins FDA IND Clearance for First Circular RNA-Based In Vivo CAR-T Therapy

RiboX Wins FDA IND Clearance for First Circular RNA-Based In Vivo CAR-T Therapy

RiboX Therapeutics receives FDA IND clearance for RXIM002, an investigational circRNA-based in vivo CAR-T therapy designed to generate CD19-targeted CAR-T cells directly inside the body for autoimmune cytopenias.

Vivo CAR-T Therapy | 10/08/2026 | By News Bureau |  269


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members